Japanese conglomerate Shimadzu Corp has set up a new business unit,called Shimadzu Biotech, which has been created to "bring together a strong solutions-based offering to accelerate the progress of biotechnology R&D." Shimadzu Biotech will encompass under one umbrella the expertise and technology from within Shimadzu Corp and its subsidiary Kratos Analytical, the firm said.
Initially, the new entity will focus on delivering a range of key products covering technologies from DNA sequencing to high-performance mass spectrometry "to provide an integrated approach to the fast-growing proteomics and genomics markets," said Shimadzu.
International feel to new entity
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze